Pathstone Holdings
CRNX icon

Pathstone Holdings’s Crinetics Pharmaceuticals CRNX Stock Holding History

Pathstone Holdings’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$844K Sell
23,228
-1,834
-7% -$81.9K ﹤0.01% 1489
2025
Q4 		$1.17M Buy
25,062
+2,186
+10% +$97.3K ﹤0.01% 1316
2025
Q3 		$953K Sell
22,876
-2,397
-9% -$76.6K ﹤0.01% 1454
2025
Q2 		$727K Sell
25,273
-3,042
-11% -$93.9K ﹤0.01% 1546
2025
Q1 		$950K Buy
28,315
+7,887
+39% +$295K ﹤0.01% 1413
2024
Q4 		$1.04M Buy
+20,428
New +$1.14M ﹤0.01% 1348

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $15.3B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.34B AUM 204.53% 1-Year Est. Return